Clinical Trials
15 trialsNCT06141031 2026-05-27
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Phase 1 Recruiting
NCT04235777 2026-05-20
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT02390518 2026-05-08
Stereotactic Radiosurgery Dose Escalation for Brain Metastases
University of Utah
Phase 1 Recruiting
NCT07075120 2026-04-30
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Recruiting
NCT05030298 2026-04-22
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
Mayo Clinic
Phase 1 Recruiting
NCT06211335 2026-03-12
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
University of California, Davis
Phase 1 Recruiting
NCT06369246 2026-03-09
PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06492954 2026-03-02
AflacST2301
Emory University
Phase 1 Recruiting
NCT07150546 2026-03-02
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Phase 1 Recruiting
NCT05488522 2026-02-20
SBRT With Atezo/Bev for HCC
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT05371132 2026-01-28
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
City of Hope Medical Center
Phase 1 Recruiting
NCT06287515 2026-01-14
Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04518748 2025-08-05
Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT04572451 2025-08-01
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
University of Pittsburgh
Phase 1 Recruiting
NCT06130826 2025-05-30
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Recruiting